Related Experiment Video
Updated: Apr 11, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Association between complete blood cell count-derived inflammatory indices and left atrial thrombus in patients with
You Zhou1, Xuewen Song2, Jifang Ma1
1Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Background:
Systemic inflammation plays a key role in thrombogenesis, yet the value of routine complete blood count-derived inflammatory indices for predicting left atrial thrombus (LAT) in patients with non-valvular atrial fibrillation (NVAF) remains unclear.
Methods:
In this cross-sectional study of 623 patients with NVAF (59 with LAT, 9.5%), we evaluated eight inflammatory indices for their association with LAT, using multivariable logistic regression and receiver operating characteristic (ROC) curve analysis.
Results:
Among the inflammatory markers analyzed, neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-mean platelet volume ratio (NMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV) were significantly associated with LAT risk after multivariable adjustment. ROC curve analysis indicated moderate predictive accuracy for these five indices, with area under the curve values ranging from 0.582 to 0.601, though no significant differences were found between them. Other indices, including monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and white blood cell-to-mean platelet volume ratio, showed no significant predictive value.
Conclusion:
NLR, NMR, SII, SIRI, and PIV are readily accessible and cost-effective inflammatory biomarkers that show association with LAT risk in NVAF patients. These indices may offer supplementary information for risk stratification in clinical practice. Their potential to guide more intensive assessment or therapeutic strategies requires further prospective validation.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Endocarditis II: Clinical Features of Infective Endocarditis
Venous Thrombosis I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Aortic Regurgitation II: Clinical Features and Diagnostic Tests

